Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) has submitted New Drug Application (NDA) for an intravenous (IV) formulation of rolapitant to the FDA

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO

100%

Additional Information

Additional Relevant Details The NDA for IV rolapitant is supported by data from a clinical program that enrolled more than 400 subjects and included a bioequivalence study and several other supportive non-clinical and clinical studies. TESARO anticipates a standard 12-month review timeline for the IV rolapitant NDA.
http://ir.tesarobio....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 14, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nda Filing, Fda Review, Rolapitant, Intravenous Administration